Kadans Science Partner has agreed to acquire Windrush Court, a life sciences building in Oxford, UK, from Oxford Biomedica for £60 million in a sale and lease back transaction.
Windrush Court is a c.75,000 sq ft building which will be leased back, in its entirety, to Oxford Biomedica.
Oxford Biomedica works across key viral vector delivery systems, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies.
Oxford is a global centre of excellence in life science innovation. The cluster is anchored by the University of Oxford which was recently named the number 1 university in the world (Times World University Ranking 2022).
The Oxford cluster spans a whole range of life sciences enterprise including drug discovery, diagnostics, medical devices, regenerative medicine and genomics. With world leading academics, researchers and clinicians, Oxford continues to be at the forefront of scientific innovation.
James Sheppard, Managing Director (UK & Ireland) said: ‘We are delighted to secure this tremendously important asset in the Oxford ecosystem. Oxford Biomedica is one of the world’s leading companies in cell & gene therapy, an area of deep specialism for Kadans, and we look forward to building a relationship with the team.’
Stuart Paynter, Chief Financial Officer of Oxford Biomedica, commented: “We are pleased to have exchanged contracts for the sale and leaseback of our state-of-the-art Windrush Court facility and look forward to building a relationship with Kadans, the European leader in the development and management of life sciences buildings and ecosystems. The proceeds of the transaction will enhance our net cash position, providing us with additional financial flexibility as we build our leadership as an innovation-led CDMO across all viral vectors for cell and gene therapy.”
